CureGate Español

Multiple myeloma clinical trials in Los Angeles

Clinical trials are research studies that test new ways to treat or manage multiple myeloma, a cancer of plasma cells in the bone marrow. Some compare a new medicine or combination with today’s standard treatment. Others study approaches such as stem cell transplant, CAR T-cell therapy or bispecific antibodies, or ways to ease side effects.

Each study has its own rules about who can join. For myeloma these often include whether it is newly diagnosed or has come back (relapsed) or stopped responding (refractory), how many lines of treatment you have had, lab results and overall health.

The list below shows multiple myeloma studies on ClinicalTrials.gov, the public U.S. registry, that list at least one recruiting site within about 50 miles of downtown Los Angeles.

Answer 4 quick questions →No records needed. See how many recruiting studies may fit. Call Aria (855) 606-1679CureGate’s assistant, in English or Spanish.

Clinical trials are research and are not guaranteed to help. CureGate does not provide medical advice.

61 recruiting multiple myeloma studies near Los Angeles

Data from ClinicalTrials.gov as of November 3, 2026. Study status can change at any time. Titles are shown as registered. Confirm details with each study team.

  1. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

    Phase
    4
    Recruiting in
    Duarte
    Last updated

  2. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

    Phase
    3
    Recruiting in
    Duarte, Irvine, Los Alamitos, Los Angeles
    Last updated

  3. A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

    Phase
    1
    Recruiting in
    Duarte, Irvine
    Last updated

  4. A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

    Phase
    3
    Recruiting in
    Duarte, Irvine, Los Angeles
    Last updated

  5. A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

    Phase
    2
    Recruiting in
    Beverly Hills, Irvine
    Last updated

  6. Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

    Phase
    1
    Recruiting in
    Duarte
    Last updated

  7. AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

    Phase
    1/2
    Recruiting in
    Duarte, Irvine
    Last updated

  8. A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

    Phase
    1
    Recruiting in
    Santa Monica
    Last updated

  9. A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Phase
    2
    Recruiting in
    Duarte, West Hollywood
    Last updated

  10. A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

    Phase
    3
    Recruiting in
    Los Angeles, Orange
    Last updated

  11. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    Phase
    not listed
    Recruiting in
    Burbank, Long Beach
    Last updated

  12. A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  13. Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

    Phase
    4
    Recruiting in
    Los Angeles
    Last updated

  14. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

    Phase
    1/2
    Recruiting in
    Duarte, Irvine
    Last updated

  15. Screening for AL Amyloidosis in Smoldering Multiple Myeloma

    Phase
    not listed
    Recruiting in
    Los Angeles
    Last updated

  16. Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

    Phase
    2
    Recruiting in
    Duarte, Irvine
    Last updated

  17. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  18. A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)

    Phase
    1
    Recruiting in
    Duarte, Irvine
    Last updated

  19. A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

    Phase
    1/2
    Recruiting in
    Duarte, Irvine
    Last updated

  20. A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Phase
    2/3
    Recruiting in
    Los Angeles
    Last updated

  21. Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

    Phase
    1/2
    Recruiting in
    Duarte
    Last updated

  22. A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

    Phase
    1/2
    Recruiting in
    Duarte
    Last updated

  23. A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

    Phase
    3
    Recruiting in
    Orange
    Last updated

  24. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

    Phase
    3
    Recruiting in
    Duarte, Irvine
    Last updated

  25. AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  26. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

    Phase
    3
    Recruiting in
    Los Angeles
    Last updated

  27. Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Phase
    2
    Recruiting in
    Los Angeles
    Last updated

  28. Horizon Two: HR NDMM (MMRC-100)

    Phase
    2
    Recruiting in
    Duarte
    Last updated

  29. A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

    Phase
    3
    Recruiting in
    Huntington Park
    Last updated

  30. A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

    Phase
    1
    Recruiting in
    Duarte
    Last updated

  31. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

    Phase
    1/2
    Recruiting in
    Duarte, Irvine
    Last updated

  32. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

    Phase
    3
    Recruiting in
    Beverly Hills, Irvine, Los Angeles, Orange
    Last updated

  33. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

    Phase
    2
    Recruiting in
    Los Angeles
    Last updated

  34. Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

    Phase
    1
    Recruiting in
    Orange
    Last updated

  35. A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

    Phase
    1
    Recruiting in
    Duarte
    Last updated

  36. A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

    Phase
    2
    Recruiting in
    Los Alamitos, Torrance, Whittier
    Last updated

  37. MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    Phase
    3
    Recruiting in
    Beverly Hills, Encino, Los Angeles, Panorama City
    Last updated

  38. Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

    Phase
    3
    Recruiting in
    Burbank
    Last updated

  39. A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  40. A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

    Phase
    1/2
    Recruiting in
    Duarte
    Last updated

  41. Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

    Phase
    1
    Recruiting in
    Los Angeles
    Last updated

  42. A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

    Phase
    1
    Recruiting in
    Duarte
    Last updated

  43. Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

    Phase
    2
    Recruiting in
    Orange
    Last updated

  44. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    Phase
    not listed
    Recruiting in
    Duarte, Glendale, Los Angeles, Orange
    Last updated

  45. Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

    Phase
    4
    Recruiting in
    Irvine, Orange
    Last updated

  46. Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    Phase
    3
    Recruiting in
    Burbank
    Last updated

  47. Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma

    Phase
    Not applicable
    Recruiting in
    Duarte, Los Angeles
    Last updated

  48. Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

    Phase
    2
    Recruiting in
    Duarte, Huntington Beach, Lancaster, Long Beach, Newport Beach, South Pasadena, Torrance, Upland
    Last updated

  49. A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

    Phase
    1/2
    Recruiting in
    Los Angeles, Orange
    Last updated

  50. Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Phase
    1
    Recruiting in
    Beverly Hills
    Last updated

  51. A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

    Phase
    3
    Recruiting in
    Beverly Hills, Pasadena
    Last updated

  52. Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

    Phase
    1
    Recruiting in
    Duarte
    Last updated

  53. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

    Phase
    1/2
    Recruiting in
    Newport Beach
    Last updated

  54. A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

    Phase
    1
    Recruiting in
    Duarte
    Last updated

  55. A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients

    Phase
    not listed
    Recruiting in
    Duarte, Irvine
    Last updated

  56. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    Phase
    not listed
    Recruiting in
    Duarte
    Last updated

  57. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

    Phase
    1/2
    Recruiting in
    Los Angeles
    Last updated

  58. A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

    Phase
    2
    Recruiting in
    West Hollywood
    Last updated

  59. A Trial of Selinexor, Ruxolitinib and Methylprednisolone

    Phase
    1
    Recruiting in
    West Hollywood
    Last updated

  60. Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

    Phase
    Early Phase 1
    Recruiting in
    West Hollywood
    Last updated

  61. A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

    Phase
    1
    Recruiting in
    Alhambra, West Hills, West Hollywood
    Last updated

Not sure where to start?

CureGate’s service is free for patients and families. CureGate research specialists can help you understand which studies may be worth asking your doctor about.

Answer 4 quick questions →No records needed. See how many recruiting studies may fit. Call Aria (855) 606-1679CureGate’s assistant, in English or Spanish.

Frequently asked questions

What if my myeloma has come back?

Many myeloma studies are for people whose myeloma has relapsed or is refractory. The number and type of past treatments (for example, which drug classes you have had) often decide which studies fit, so a list of past treatments is very helpful.

What is a clinical trial?

A clinical trial is a research study with people. It tests whether a new medicine, combination, procedure or approach is safe and how well it works compared with what is used today. Taking part is always voluntary, and you can leave a study at any time.

How do I know if a study fits?

Every study lists who can join (eligibility criteria), such as the exact type and stage of cancer, test results, past treatments and overall health. Only the study team can confirm eligibility. Your oncologist can help you decide whether a study is worth a closer look.

Does it cost anything to take part in a study?

It depends on the study. Some costs may be covered by the study and others billed to insurance. Ask the study team what is covered before you decide. CureGate’s matching service itself is free for patients and families.

Is CureGate running these studies?

No. CureGate is an independent matching service. The studies listed here are run by their sponsors and research sites, and a listing on this page is not a recommendation of any study.

How often is this list updated?

The list comes from ClinicalTrials.gov and shows the date it was pulled. A study’s status can change at any time, so always confirm details with the study team.

How can CureGate help?

CureGate’s service is free. Answer four quick questions (no records needed) to see how many recruiting studies may fit, call Aria at (855) 606-1679, or ask a CureGate research specialist to call you back. Nothing is shared with a study site unless you say so.

Can I search for a family member?

Yes. Many people use CureGate for a parent, spouse or friend, with that person’s permission.

Clinical trials are research and are not guaranteed to help. CureGate does not provide medical advice.